Baseline serum PINP level is associated with the increase in hip bone mineral density seen with Romosozumab treatment in previously untreated women with osteoporosis - Kashii, Masafumi; Kamatani, Takashi; Nagayama, Yoshio; Miyama, Akira; Tsuboi, Hideki; Ebina, Kosuke (Osteoporosis international, 2023)
Keywords: Aged; Biomarkers - blood; Bone density; Bone Density - drug effects; Bone Density Conservation Agents - pharmacology; Bone Density Conservation Agents - therapeutic use; Bone mineral density; Bone turnover; Endocrinology; Female; Femur; Femur Neck - diagnostic imaging; Femur Neck - drug effects; Hip; Humans; Lumbar Vertebrae - diagnostic imaging; Lumbar Vertebrae - drug effects; Medicine; Medicine & Public Health; Monoclonal antibodies; Multiple regression analysis; Original Article; Orthopedics; Osteoporosis; Osteoporosis, Postmenopausal - blood; Osteoporosis, Postmenopausal - diagnostic imaging; Osteoporosis, Postmenopausal - drug therapy; Pelvic Bones - diagnostic imaging; Pelvic Bones - drug effects; Post-menopause; Procollagen; Procollagen - blood; Prospective Studies; Rheumatology; Spine (lumbar); Teriparatide; Bone mineral density; Romosozumab; Postmenopausal osteoporosis; Type I procollagen N-terminal propeptide; Responder analysis